The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts by performing high-priority clinical studies and trials to test therapeutics for the Coronavirus Disease 2019 (COVID-19).
NCATS is soliciting applications for Emergency Competitive Revisions to Existing NIH Awards (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients for clinical studies and trials in support of COVID-19 therapeutic interventions as follows:
- RFA-TR-15-002- CTSA Network - Trial Innovation Centers (TICs) (U24)
- RFA-TR-15-004- Clinical and Translational Science Award (CTSA) Network Recruitment Innovation Centers (RICs) (U24)
- PAR-18-940 - Clinical and Translational Science Award (U54 Clinical Trial Optional) UL1 Component Only
- PAR-18-464 - Clinical and Translational Science Award (U54 Clinical Trial Optional) UL1 Component Only
- PAR-15-304 - Clinical and Translational Science Award (U54 Clinical Trial Optional) UL1 Component Only
NCATS expects to issue 1-8 awards for clinical studies and trials in support of COVID-19 therapeutic interventions.